Kisspeptin-10 is the ten-amino-acid, amidated end of the human kisspeptin family. It activates a receptor upstream of gonadotropin-releasing hormone, allowing researchers to examine how the brain stimulates reproductive hormones. Human experiments have demonstrated changes in luteinizing hormone, its pulse pattern and, in some settings, testosterone. The response depends on sex, menstrual phase, the underlying disorder and the pattern of experimental exposure. A 2026 study extends these physiological observations to twelve days in healthy men, while clinical fertility and sexual-symptom outcomes remain separate questions.
Overview
The KISS1 gene produces a precursor from which several kisspeptins can be formed. Kisspeptin-54, originally named metastin after its isolation from placenta, contains the same receptor-active C-terminal region found in kisspeptin-10. The ten-residue human peptide ends in an amide group and has sequence YNWNSFGLRF-NH2. These terminal features are part of its chemical identity. Ohtaki and colleagues (2001); original sequence context.
Molecular profile
Forms and derivatives
Human kisspeptin-10 salt preparations
An acetate or another salt designation describes the counterion associated with the amidated peptide. Clinical correspondence also requires the actual preparation and route.
Kisspeptin-13, -14 and -54
Related endogenous lengths share the receptor-active C-terminal region. The longer forms have their own exposure and human-study findings.
[D-Tyr1]kisspeptin-10
An analogue replacing the first tyrosine with its D form. Curtis and colleagues found stronger hormone responses than parent KP10 in male mice despite lower receptor affinity in binding assays.
The related 13-, 14- and 54-residue forms share a receptor-binding region, but length and breakdown influence the effect of a particular preparation in the body. Clinical reports identifying kisspeptin-54 therefore remain attached to that form. Kotani and colleagues (2001).
Uses and research areas
Kisspeptin-10 has principally served as a research probe of the reproductive endocrine axis. Studies have examined healthy men and women, men with type 2 diabetes and mildly low testosterone, and patients with specific genetic defects affecting neurokinin B signaling. Investigators use serial hormone sampling to ask whether stimulation reaches the downstream pituitary and gonads.
That chain makes the peptide interesting for reproductive disorders, but LH and testosterone measurements alone do not establish pregnancy, improved sperm production or relief of sexual symptoms. The published IVF egg-maturation and sexual-brain imaging studies discussed elsewhere in this library chiefly used kisspeptin-54. George and colleagues (2013); Young and colleagues (2013).
Mechanism of action
KISS1R, historically called GPR54, is a receptor on the signaling pathway that activates GnRH neurons. GnRH then stimulates the pituitary gland to release LH and follicle-stimulating hormone. These hormones act at the testes or ovaries, influencing sex-steroid production and reproductive activity. GnRH's pulse pattern matters because the pituitary responds to timing as well as to the presence of a signal. Human receptor mutations associated with failure of normal pubertal development provide evidence for the pathway's importance. Seminara and colleagues (2003).
Neurokinin B participates further upstream in this network. In patients with TAC3 or TACR3 defects, kisspeptin-10 restored measurable LH pulses during monitored infusion, helping place the neurokinin signal before kisspeptin stimulation. The experiment required a functioning downstream pathway; a KISS1R defect would present a different biological problem. Young and colleagues (2013).
Pharmacokinetics
Kisspeptin concentration and the release of reproductive hormones describe two connected processes. Physiological studies have sampled plasma kisspeptin during intravenous experiments, while LH sampling follows the downstream hormone response. In one study, kisspeptin-10 increased gonadotropins in men and preovulatory women, but the tested follicular-phase experiments did not establish a clear increase. A kisspeptin-54 comparison retained a response in that setting. In a separate experiment in the same report, the blood antibody test’s kisspeptin signal fell by half in about four minutes after the intravenous infusion stopped. This measurement follows material recognized by the antibody; it does not confirm that all of the signal came from intact kisspeptin-10. Jayasena and colleagues (2011).
No exposure curve is supplied here: the acquired primary extraction does not provide a complete peptide-specific concentration series and sufficiently resolved pharmacokinetic analysis for the tested preparation. The duration of an LH rise or a twelve-day stimulation experiment cannot supply the peptide's elimination half-life.
Research findings
Acute stimulation and LH pulses in men
George and colleagues demonstrated rapid LH stimulation in healthy men in small intravenous experiments. In one four-person infusion comparison, mean LH rose from 5.2 to 14.1 IU/L and pulse frequency from 0.7 to 1.0 per hour. Other subgroups examined different exposure conditions, so those four participants do not represent a pooled denominator for the whole publication. The strongest conclusion is that the short peptide can influence reproductive-hormone release in humans. George and colleagues (2011).
Sex, menstrual phase and low-testosterone settings
Jayasena's study recruited 35 women and 11 men, with smaller subgroups used in each experiment. Kisspeptin-10 increased gonadotropins in men and preovulatory women, while the tested follicular-phase experiments produced no significant response. A specified kisspeptin-54 comparison retained a response in that setting. The results show why the two forms and the cycle phase belong in an account of the findings. Jayasena and colleagues (2011).
A separate proof-of-concept study involved five men with type 2 diabetes and mild biochemical hypogonadism plus seven healthy comparators. In the four affected men who underwent the longer infusion experiment, testosterone increased from 8.5 to 11.4 nmol/L. The brief endocrine response showed a stimulable axis in these participants, with sustained treatment outcomes awaiting different studies. George and colleagues (2013).
A specific genetic pathway experiment
Young and colleagues studied three men and one woman with neurokinin B pathway defects on two sampling days: one with a control liquid containing no kisspeptin and one with kisspeptin-10. LH pulse frequency increased from approximately 0.1 to 0.5 per hour, and sex-steroid or inhibin responses were observed. These measurements supported the proposed signaling sequence while leaving restored fertility untested. Original report.
Longer physiological exposure in 2026
Yeung and colleagues recruited 15 healthy men across partly overlapping experiments, with 12 serving as controls given a preparation without kisspeptin. Acute subcutaneous exposure increased LH, FSH and testosterone. During continuous exposure, gonadotropin levels approached those in the controls by day five although testosterone remained elevated; a separate intermittent experimental exposure retained gonadotropin responses over twelve days. The different patterns make desensitization a contextual finding rather than an inevitable response to every exposure. This small study measured hormones in healthy men, with no fertility or sexual-symptom efficacy endpoint. Yeung and colleagues (2026).
Safety and tolerability
The four-person genetic-pathway study reported no adverse events related to kisspeptin or the control liquid without kisspeptin. That monitored experience contributes useful short-term observations, but it supplies little information about uncommon events, reproductive consequences or prolonged treatment across broader populations. Young and colleagues (2013).
FDA's 2024 compounding review describes kisspeptin-10 as an investigational substance and identifies insufficient treatment safety information for proposed uses and routes. Peptide impurities and aggregation can also affect immune responses. The 2026 healthy-men experiment updates duration of physiological observation; its size and population leave those larger treatment-safety questions open. No FDA-approved kisspeptin-10 therapeutic product was identified in this review. FDA briefing; Yeung and colleagues (2026).
What the research means
Kisspeptin-10 provides evidence that a short receptor-active peptide can stimulate the human reproductive axis and help locate defects within it. The studies become easier to interpret when the reader follows the sequence from kisspeptin exposure through LH/FSH to gonadal hormones, and then asks whether a clinical outcome was measured.
The 2026 findings make sustained experimental stimulation more plausible under selected conditions. Fertility treatment would additionally need evidence about reproductive outcomes, the relevant disorder and longer safety; sexual-desire treatment would need direct symptom trials. Those are the next links in the chain beyond the hormone responses described here.
FAQs
Does an LH increase prove improved fertility?
LH indicates that part of the reproductive axis responded. Fertility also depends on ovarian or testicular function and other factors, so it requires reproductive outcomes such as pregnancies or births rather than hormone values alone.
Why did women respond differently across menstrual phases?
The ovarian hormonal setting changes the sensitivity of the reproductive axis. In Jayasena’s small experiments, the short peptide produced different gonadotropin responses in follicular and preovulatory conditions. Original study.
What changed with the 2026 study?
The study added short-term repeated-exposure physiology in healthy men and showed that continuous and intermittent exposure could have different gonadotropin responses. It did not measure pregnancies or treatment of sexual symptoms. Yeung and colleagues.
Is kisspeptin-10 the form used in the main IVF and sexual-imaging reports?
The reports discussed on the kisspeptin-54 page used the 54-residue peptide. Shared receptor activity makes the comparison useful, but each result remains attached to its tested form.
Comparisons and related reading
Kisspeptin-54 offers the most useful comparison because it shares the receptor-active end while having a different molecular length and clinical research program. Bremelanotide and oxytocin approach sexual or reproductive biology through other receptor systems and illustrate the importance of separating a laboratory response from a demonstrated treatment outcome.
References
Small IV experiments in healthy men measured LH in repeated blood samples. Kisspeptin-10 increased LH concentration and, in a four-person comparison, the frequency of LH pulses.
A shared receptor-binding region did not produce identical responses across hormonal contexts.
- George JT, Veldhuis JD, Tena-Sempere M, Millar RP, Anderson RA. Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clinical endocrinology. 2013;79(1):100–104. DOI: 10.1111/cen.12103. · onlinelibrary.wiley.com
The reproductive axis responded during brief monitored exposure.
A functioning downstream pathway could be stimulated in this specific genetic condition.
The placenta-derived amidated 54-residue peptide establishes metastin identity and the original receptor-ligand discovery.
Identifies related endogenous peptide lengths and receptor signaling in the original ligand-discovery experiments.
The original analogue experiment states the amidated human C-terminal decapeptide sequence.
Evaluates the investigational peptide, proposed routes, limited treatment safety data and impurity/aggregation concerns.
Human mutations and a mouse knockout connect receptor function to pubertal reproductive-axis activity.
In healthy men, the 2026 study compared one-time, continuous and intermittent subcutaneous exposure. LH and FSH responses weakened during continuous exposure, while a separate intermittent experiment retained responses over twelve days.
Glossary
- GnRH
- Gonadotropin-releasing hormone, the hypothalamic signal that stimulates pituitary LH and FSH release.
- LH
- Luteinizing hormone, a pituitary hormone that influences gonadal steroid production and ovulation.
- FSH
- Follicle-stimulating hormone, a pituitary hormone involved in ovarian follicle development and testicular sperm-production support.
- Hypogonadism
- Reduced gonadal function; its cause may lie in the gonads or in upstream hormonal signaling.
- Desensitization
- A reduced response during continuing or repeated stimulation, influenced by biological setting and exposure pattern.